Racura Oncology Ltd (ASX:RAC)

Racura Oncology Statistics

Total Valuation

Racura Oncology has a market cap or net worth of AUD 462.89 million. The enterprise value is 441.95 million.

Market Cap	462.89M
Enterprise Value	441.95M

Important Dates

The next estimated earnings date is Thursday, May 28, 2026.

Earnings Date	May 28, 2026
Ex-Dividend Date	n/a

Share Statistics

Racura Oncology has 182.24 million shares outstanding. The number of shares has increased by 2.69% in one year.

Current Share Class	182.24M
Shares Outstanding	182.24M
Shares Change (YoY)	+2.69%
Shares Change (QoQ)	+2.47%
Owned by Insiders (%)	27.91%
Owned by Institutions (%)	2.61%
Float	127.28M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	133.14
PB Ratio	19.64
P/TBV Ratio	21.86
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-47.07
EV / Sales	127.12
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 18.37

Current Ratio	18.37
Quick Ratio	18.15
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -42.40% and return on invested capital (ROIC) is -22.98%.

Return on Equity (ROE)	-42.40%
Return on Assets (ROA)	-21.91%
Return on Invested Capital (ROIC)	-22.98%
Return on Capital Employed (ROCE)	-34.48%
Weighted Average Cost of Capital (WACC)	8.74%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.15
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +122.81% in the last 52 weeks. The beta is 0.82, so Racura Oncology's price volatility has been lower than the market average.

Beta (5Y)	0.82
52-Week Price Change	+122.81%
50-Day Moving Average	2.39
200-Day Moving Average	2.40
Relative Strength Index (RSI)	51.48
Average Volume (20 Days)	206,768

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Racura Oncology had revenue of AUD 3.48 million and -9.39 million in losses. Loss per share was -0.05.

Revenue	3.48M
Gross Profit	2.97M
Operating Income	-8.14M
Pretax Income	-9.39M
Net Income	-9.39M
EBITDA	-7.86M
EBIT	-8.14M
Loss Per Share	-0.05

Balance Sheet

The company has 20.94 million in cash and n/a in debt, with a net cash position of 20.94 million or 0.11 per share.

Cash & Cash Equivalents	20.94M
Total Debt	n/a
Net Cash	20.94M
Net Cash Per Share	0.11
Equity (Book Value)	23.57M
Book Value Per Share	0.13
Working Capital	20.07M

Cash Flow

Operating Cash Flow	-7.33M
Capital Expenditures	n/a
Depreciation & Amortization	281,196
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 85.30%, with operating and profit margins of -234.15% and -270.04%.

Gross Margin	85.30%
Operating Margin	-234.15%
Pretax Margin	-270.04%
Profit Margin	-270.04%
EBITDA Margin	-226.07%
EBIT Margin	-234.15%
FCF Margin	n/a

Dividends & Yields

Racura Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.69%
Shareholder Yield	-2.69%
Earnings Yield	-2.03%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Racura Oncology has an Altman Z-Score of 155.8 and a Piotroski F-Score of 2.

Altman Z-Score	155.8
Piotroski F-Score	2